Drug Trial Radar · NCT00233532
Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)
Last checked: Nov 20, 2026Latest source record: Jul 22, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,000
Actual
Start
Mar 2004
Primary completion
Jun 2005
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- Oct 6, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor, trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.
Conditions
- Hypertension
Interventions
TrandolaprilDrug
0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effectiveness of escalating dose regimen of trandolapril in controlling blood pressureTime frame: 14 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.